Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis-Reference-Cited by-同舟云学术

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

Published:2002-01-01 Issue:1 Volume:99 Page:381-383
ISSN:1528-0020
Container-title:Blood
language:en
Short-container-title:

Author:

Beham-Schmid Christine¹,Apfelbeck Ute¹,Sill Heinz¹,Tsybrovsky Oleksiy¹,Höfler Gerald¹,Haas Oskar A.¹,Linkesch Werner¹

Affiliation:

1. From the Institute of Pathology and the Division of Hematology, Department of Medicine, Karl-Franzens University, Graz, Austria; and the Children's Cancer Research Institute, St Anna Children's Hospital, Vienna, Austria.

Abstract

Morphologic bone marrow changes in patients with BCR-ABL–positive chronic myelogenous leukemia (CML) were investigated during treatment with the tyrosine kinase inhibitor STI571. Bone marrow trephine biopsy specimens from 23 pretreated patients with CML were examined morphologically and by morphometry before and 6 weeks and 3 months after the initiation of STI571 therapy (Glivec, Novartis, Basel, Switzerland). Bone marrow changes during treatment showed a quantitative normalization of erythropoiesis, a marked reduction of granulopoiesis, and a significant decrease in megakaryocytes with the reappearance of normal-sized forms. Furthermore, a significant regression of bone marrow fibrosis was observed in patients with initial fibrosis (P < .000 000 001). These results may expand the profile of STI571 and may offer novel therapeutic possibilities in diseases with bone marrow fibrosis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/99/1/381/1679334/h80102000381.pdf

Reference19 articles.

1. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining.;Rowley;Nature.,1973

2. Targeted therapies for the myeloid leukaemias.;Maslak;Expert Opin Investig Drugs.,2000

3. Efficacy and safety of a specific inhibitor to the BCR-ABL tyrosine kinase in chronic myeloid leukemia.;Druker;N Engl J Med.,2001

4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.;Druker;N Engl J Med.,2001

5. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.;O′Dwyer;Curr Opin Oncol.,2000

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients;Frontiers in Pharmacology;2023-07-04

2. Cromolyn sodium and masitinib combination inhibits fibroblast-myofibroblast transition and exerts additive cell-protective and antioxidant effects in a bleomycin-induced in vitro fibrosis model;2022-08-16

3. Understanding and Therapeutically Targeting the Scleroderma Myofibroblast;Current Treatment Options in Rheumatology;2022-03

4. The extracellular matrix: A key player in the pathogenesis of hematologic malignancies;Blood Reviews;2021-07

5. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition;Translational Research;2021-05